Navigation Links
Acute Pain Global Clinical Trials Review, H2, 2013
Date:11/27/2013

London (PRWEB) November 27, 2013

Acute Pain Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, “Acute Pain Global Clinical Trials Review, H2, 2013" provides data on the Acute Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Pain. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

-Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
-Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
-Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

-Understand the dynamics of a particular indication in a condensed manner
-Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
-Obtain discontinued trial listing for trials across the globe
-Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

Table of Con
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
2. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
3. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
4. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
7. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
8. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
10. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
11. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014) – The severe flooding that devastated a wide ... destructive if the bridges, roads and other infrastructure had ... from the University of Colorado Denver. , "People need ... Jimmy Kim, PhD, associate professor of structural engineering at ... and lead author the study. "There is an assumption ...
(Date:10/27/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) today ... the immunological response triggered by its novel proprietary ... of relapse in breast cancer patients. The AE37 ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... , October 27, 2014 Investor-Edge ... Inc. (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... As the Office of Naval Research (ONR) increases its ... number of hurdles need to be overcome including autonomy ... an Aug. 18 conference on unmanned systems. "We ... for the Navy and Marine Corps," said Dr. Larry ...
... developed new nano-structured glass, turning it into new type ... and will significantly reduce the cost of medical imaging. ... converter created by femtosecond laser nanostructuring of glass published ... by Professor Peter Kazansky at the University,s Optoelectronics Research ...
... Aug. 18, 2011 CBI is pleased to announce ... and Post-Approval Studies Congress, being held September 20-22, 2011 ... an impressive speaker lineup from Celgene, Covidien, FDA, Forest, ... more. Attendees have the opportunity to ...
Cached Biology Technology:Office of Naval Research taking on challenges of unmanned underwater vehicles 2New nanostructured glass for imaging and recording 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:10/28/2014)... tragic realities of cancer is that the drugs ... their effectiveness varies unpredictably from patient to patient. ... change this reality by rapidly assessing how effective ... cancer before chemotherapy begins. , A team of ... Professor Melissa Skala has developed the technique, which ...
(Date:10/28/2014)... Researchers from the National University of Singapore (NUS) have ... - breeding and laying direct developing eggs in live ... the white spotted bush frog ( Raorchestes chalazodes ... of two species known to adopt this novel reproductive ... of London,s Biological Journal of the Linnean Society ...
(Date:10/27/2014)... University researchers have delivered a scientific one-two punch with ... fibers self-assemble via their sticky ends. , Collagen is ... of bone and the fibrous tissues that support cells ... to better synthetic collagen for tissue engineering and cosmetic ... Hartgerink has been studying synthetic collagen for a decade, ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... team of French and German researchers report in the ... http://www.fasebj.org ) that people with limb-girdle muscular dystrophy are ... to prevent the loss of muscle tissue. By targeting ... protein, scientists could develop new drugs to stop muscle ...
... thing could be harmful to the environment. For years, ... bacteria and, recently, have used this knowledge to create ... Missouri researcher has found that silver nanoparticles also may ... from wastewater treatment systems. The study was funded by ...
... and Canadian scientists expect to begin trials next month (May) ... of energy trapped in the world,s unrecoverable heavy oil deposits. ... because the oil has become either solid or too thick ... conventional means. , However, scientists at Newcastle University, England, and ...
Cached Biology News:Researchers discover molecular basis of a form of muscular dystrophy 2Too much technology may be killing beneficial bacteria 2Scientists aim to boost world energy supplies -- with microbes! 2Scientists aim to boost world energy supplies -- with microbes! 3Scientists aim to boost world energy supplies -- with microbes! 4